FREE PHENOWEBINARS
Stephanie J. Marin is the Applied Markets Global Market Development Manager at Phenomenex. She received her Ph.D. in chemistry from Arizona State University, and has expertise in sample preparation, liquid chromatography and mass spectrometry. Dr Marin has worked in marketing, product development, method development and method validation, in addition to customer facing roles in technical support, service, education and training. She has over 10 years of experience developing and validating clinical methods from her tenure at the ARUP Institute for Clinical and Experimental Pathology. She has also held positions as an Applications Chemist at Hamilton Company and Biotage, Marketing Manager at Selerity Technologies and as a Group Leader in analytical services for specialty chemicals and polymers at Rohm and Haas (now Dow). She was also a supervisor at an EPA certified laboratory. She is the author of over 30 peer reviewed publications and book chapters and over 100 abstracts presented at national and international meetings.
- The differences between fully porous polar C18 and core-shell biphenyl LC column chemistries
- Analyte properties affect LC column retention and selectivity
- LC-MS/MS methods for analysis of antipsychotics, antidepressants, and anticonvulsants
- Column solution for LC-MS screening of 48 TDM drug analytes for toxicology applications
- Review selectivity and retention on polar C18 and biphenyl column chemistries for antipsychotic, antidepressant, and anticonvulsant drugs
- Learn how analyte properties for these drug classes affect LC column choice
- Take a deep dive into optimized LC separations for screening and confirmation of antipsychotic, antidepressant, and anticonvulsant drugs
- Clinical and forensic toxicologists who want to know which columns to choose for their LC-MS/MS methods for TDM (prescribed) drugs in clinical research and forensic toxicology applications
